IBR822 / Imbioray Bio - LARVOL DELTA

InBio completed nearly RMB 100 million in Series A+ financing, led by Huarui Investment [Google translation] (Sohu.com) - "According to the news from the investment community on January 22, Inbio (Hangzhou) Biopharmaceutical Co., Ltd...recently completed a round of A+ financing of nearly 100 million yuan. This round of financing was led by Huarui Investment, followed by Tailong Investment, Sunzi Technology, Huayi Capital, and Binjiang 5050 Fund. This round of financing is mainly used for the global FIC (first-in-class) universal natural killer cell therapy, that is, the registration clinical projects of innovative biological products such as IBR854, IBR733, IBR822, and IBR900, and to accelerate the launch of a series of original innovative peripheral blood-derived, non-viral vector, non-gene-edited spot universal immune-tamed NK/CAR-raNK and tiNK cell products."

Financing • Hematological Malignancies • Solid Tumor

INBio: Phase I clinical trial of the world’s first Trop-2 CAR-NK cell product officially launched [Google translation] (vbdata.cn) - "IBR Biopharm has launched the Phase I clinical trial of IBR822, the world's first Trop-2 CAR-NK cell product, led by Zhejiang Cancer Hospital and in collaboration with multiple hospitals. It aims to treat solid tumors. Early clinical trials have shown that it has a significant killing effect on a variety of tumors."

New P1 trial • Oncology • Solid Tumor